LINC00160 and breast carcinoma: Wu et al. also showed that LINC00160 might mediate paclitaxel/doxorubicin resistance in breast cancer cells by recruiting CCAAT/enhancer binding protein β to the trefoil factor 3 (intestinal) promoter [40].